Mostafid H - Search Results

1

Advances in intravesical drug delivery systems to treat bladder cancer.

Kolawole OM, Lau WM, Mostafid H, Khutoryanskiy VV. Kolawole OM, et al. Among authors: mostafid h. Int J Pharm. 2017 Oct 30;532(1):105-117. doi: 10.1016/j.ijpharm.2017.08.120. Epub 2017 Sep 1. Int J Pharm. 2017. PMID: 28867449 Review.

2

Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer.

Simpson GR, Horvath A, Annels NE, Pencavel T, Metcalf S, Seth R, Peschard P, Price T, Coffin RS, Mostafid H, Melcher AA, Harrington KJ, Pandha HS. Simpson GR, et al. Among authors: mostafid h. Br J Cancer. 2012 Jan 31;106(3):496-507. doi: 10.1038/bjc.2011.577. Epub 2012 Jan 12. Br J Cancer. 2012. PMID: 22240799 Free PMC article.

3

Urothelial cancer: a narrative review of the role of novel immunotherapeutic agents with particular reference to the management of non-muscle-invasive disease.

Doyle E, Crew J, Mostafid H, Tuthill M, Cerundolo V, Gerristen W, Protheroe A. Doyle E, et al. Among authors: mostafid h. BJU Int. 2019 Jun;123(6):947-958. doi: 10.1111/bju.14643. Epub 2019 Jan 22. BJU Int. 2019. PMID: 30548196 Review.

4

Treatment options and results of adjuvant treatment in nonmuscle-invasive bladder cancer (NMIBC) during the Bacillus Calmette-Guérin shortage.

Fankhauser CD, Teoh JY, Mostafid H. Fankhauser CD, et al. Among authors: mostafid h. Curr Opin Urol. 2020 May;30(3):365-369. doi: 10.1097/MOU.0000000000000739. Curr Opin Urol. 2020. PMID: 32141939 Free article. Review.

5

Neoadjuvant Intravesical Therapy for Non-muscle-invasive Bladder Cancer: A New Approach for Old Agents?

Mostafid H. Mostafid H. Eur Urol. 2020 Dec;78(6):863-864. doi: 10.1016/j.eururo.2020.07.026. Epub 2020 Aug 9. Eur Urol. 2020. PMID: 32782072 No abstract available.

6

No 'one size fits all' approach in the management of high-risk non-muscle invasive bladder cancer.

Mostafid H. Mostafid H. Scand J Urol. 2021 Feb;55(1):53. doi: 10.1080/21681805.2020.1866661. Epub 2021 Jan 11. Scand J Urol. 2021. PMID: 33427558 No abstract available.

7

What influences adherence to guidance for postoperative instillation of intravesical chemotherapy to patients with bladder cancer?

Dunsmore J, Duncan E, Mariappan P, de Bruin M, MacLennan S, Dimitropoulos K, Kasivisvanathan V, Mostafid H, Briganti A, N'Dow J, MacLennan S. Dunsmore J, et al. Among authors: mostafid h. BJU Int. 2021 Aug;128(2):225-235. doi: 10.1111/bju.15336. Epub 2021 Mar 28. BJU Int. 2021. PMID: 33450116

8

Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer.

Pijpers OM, Hendricksen K, Mostafid H, de Jong FC, Rosier M, Mayor N, de Jong JJ, Boormans JL. Pijpers OM, et al. Among authors: mostafid h. Urol Oncol. 2022 Feb;40(2):62.e13-62.e20. doi: 10.1016/j.urolonc.2021.07.019. Epub 2021 Aug 30. Urol Oncol. 2022. PMID: 34470725 Free article.

9

Therapeutic options in the management of intermediate-risk nonmuscle-invasive bladder cancer.

Horvath A, Mostafid H. Horvath A, et al. Among authors: mostafid h. BJU Int. 2009 Mar;103(6):726-9. doi: 10.1111/j.1464-410X.2008.08094.x. Epub 2008 Oct 24. BJU Int. 2009. PMID: 19007379 Review.

10

Measuring and improving the quality of transurethral resection for bladder tumour (TURBT).

Mostafid H, Brausi M. Mostafid H, et al. BJU Int. 2012 Jun;109(11):1579-82. doi: 10.1111/j.1464-410X.2011.10638.x. Epub 2011 Oct 12. BJU Int. 2012. PMID: 21992712 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

84 results

Search Page